Electricity from photovoltaic solar cells: Flat-Plate Solar Array Project final Report. Volume III: Silicon sheet: wafers and ribbons

The Flat-Plate Solar Array (FSA) Project, funded by the U.S. Government and managed by the Jet Propulsion Laboratory, was formed in 1975 to develop the module/array technology needed to attain widespread terrestrial use of photovoltaics by 1985. To accomplish this, the FSA Project established and managed an Industry, University, and Federal Government Team to perform the needed research and development. The primary objective of the Silicon Sheet Task of the FSA Project was the development of one or more low-cost technologies for producing silicon sheet suitable for processing into cost-eompetitive solar cells. Silicon sheet refers to high-purity crystalline silicon of size and thickness for fabrication into solar cells. The Task effort began with state-of-the-art sheet technologies and then solicited and supported any new silicon sheet alternatives that had the potential to achieve the Project goals. A total of 48 contracts were awarded that covered work in the areas of ingot growth and casting, wafering, ribbon growth, other sheet technologies, and programs of supportive research. Periodic reviews of each sheet technology were held, assessing the technical progress and the long-range potential. Technologies that failed to achieve their promise, or seemed to have lower probabilities for success in comparison with others, were dropped. A series of workshops was initiated to assess the state of the art, to provide insights into problems remaining to be addressed, and to support technology transfer. The Task made and fostered significant improvements in silicon sheet including processing of both ingot and ribbon technologies. An additional important outcome was the vastly improved understanding of the characteristics associated with high-quality sheet, and the control of the parameters required for higher efficiency solar cells. Although significant sheet cost reductions were made, the technology advancements required to meet the Task cost goals were not achieved. This FSA Final Report (JPL Publication 86-31, 5101-289, DOE/JPL 1012-125, October 1986) is composed of eight volumes, consisting of an Executive Summary and seven technology reports: Volume I: Executive Summary. Volume II: Silicon Material. Volume III: Silicon Sheet: Wafers and Ribbons Volume IV: High-Efficiency Solar Celis. Volume V: Process Development. Volume VI: Engineering Sciences and Reliability. Volume VII: Module Encapsulation. Volume VIII: Project Analysis and Integration. Two supplemental reports included in the final report package are: FSA Project: 10 Years of Progress, JPL Document 400-279. 5101-279, October 1985. Summary of FSA Project Documentation: Abstracts of Published Documents, 1975 to 1986, JPL Publication 82-79 (Revision 1),5101-221, DOE/JPL-1 012-76, September 1986

Global Answers to Global Problems: Health as a Global Public Good. 1/2007

Address by Jorge Sampaio, UN Secretary-General's Special Envoy to Stop Tuberculosis and former President of Portugal, on the occasion of the 8th Hendrik Brugmans Memorial Lecture to celebrate the 100th anniversary of Hendrik Brugmans, sponsored by the College of Europe, the Madariaga Foundation and the Alumni Association of the College of Europe, Brussels City Hall, 14 December 2006

Lifespan extension and the doctrine of double effect

Recent developments in biogerontology—the study of the biology of ageing—suggest that it may eventually be possible to intervene in the human ageing process. This, in turn, offers the prospect of significantly postponing the onset of age-related diseases. The biogerontological project, however, has met with strong resistance, especially by deontologists. They consider the act of intervening in the ageing process impermissible on the grounds that it would (most probably) bring about an extended maximum lifespan—a state of affairs that they deem intrinsically bad. In a bid to convince their deontological opponents of the permissibility of this act, proponents of biogerontology invoke an argument which is grounded in the doctrine of double effect. Surprisingly, their argument, which we refer to as the ‘double effect argument’, has gone unnoticed. This article exposes and critically evaluates this ‘double effect argument’. To this end, we first review a series of excerpts from the ethical debate on biogerontology in order to substantiate the presence of double effect reasoning. Next, we attempt to determine the role that the ‘double effect argument’ is meant to fulfil within this debate. Finally, we assess whether the act of intervening in ageing actually can be justified using double effect reasoning

Does the Pharmaceutical Sector Have a Coresponsibility for the Human Right to Health?

The highest attainable standard of health is a fundamental human right, which has been part of international law since 1948. States and their institutions are the primary duty bearers responsible for ensuring that human rights are respected, protected, and fulfilled. However, more recently it has been argued that pharmaceutical companies have a coresponsibility to fulfill the human right to health. Most prominently, this coresponsibility has been expressed in the United Nations (UN) Millennium Goal 8 Target 4. “In cooperation with pharmaceutical companies, provide access to affordable essential drugs in developing countries.

Frontline Issues in Nutrition Assistance

Frontline Issues in Nutrition Assistance: Hunger 2006 argues the fastest, most direct way to reduce hunger is to improve nutrition assistance programs. In the United States, the government has pledged to cut hunger in half by 2010. Will it happen? Not without an aggressive approach. Internationally, we also find ourselves pursuing another deadline, the Millennium Development Goals (MDGs). The MDGs, including the first goal of halving hunger, come due in 2015. Presently, we are not on track to reach that goal in some of the worst stricken areas of the world.Nutrition assistance programs have been proven highly effective and affordable. Hunger 2006 calls for strengthening these. In the United States, that means improving existing federal programs. In the developing world, we focus on nutrition interventions that will have an immediate impact on the most vulnerable groups, especially women and children. The time is now for stepping up efforts to end hunger, and Hunger 2006 shows how to do it

An argument for the use of Aristotelian method in bioethics

The main claim of this paper is that the method outlined and used in Aristotle's Ethics is an appropriate and credible one to use in bioethics. Here “appropriate” means that the method is capable of establishing claims and developing concepts in bioethics and “credible” that the method has some plausibility, it is not open to obvious and immediate objection. It begins by suggesting why this claim matters and then gives a brief outline of Aristotle's method. The main argument is made in three stages. First, it is argued that Aristotelian method is credible because it compares favourably with alternatives. In this section it is shown that Aristotelian method is not vulnerable to criticisms that are made both of methods that give a primary place to moral theory (such as utilitarianism) and those that eschew moral theory (such as casuistry and social science approaches). As such, it compares favourably with these other approaches that are vulnerable to at least some of these criticisms. Second, the appropriateness of Aristotelian method is indicated through outlining how it would deal with a particular case. Finally, it is argued that the success of Aristotle's philosophy is suggestive of both the credibility and appropriateness of his method.</p